SCHEMBL5361349

SCHEMBL5361349

Cc1c2ccn[c]c2cc2c1[nH]c1ccc(O)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 4/20 0.51
PDGFRA P16234 2/20 0.51
FGFR3 P22607 2/20 0.51
BCHE P06276 2/20 0.44
ACHE P22303 2/20 0.44
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
HTR5A P47898 1/20 0.39
NR1I2 O75469 1/20 0.38
NQO2 P16083 1/20 0.37
CHEK1 O14757 3/20 0.37
WEE1 P30291 2/20 0.37
ROCK2 O75116 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HTR1D P28221 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24276808 0.76 KIT (0.64) KITPDGFRAFGFR3BCHEACHE
SCHEMBL614704 0.75 KIT (0.53) KITPDGFRAFGFR3BCHEACHE
SCHEMBL6456554 0.71 MAOA (0.61) KITPDGFRAFGFR3BCHEACHE
SCHEMBL12387156 0.69 KIT (0.47) KITPDGFRAFGFR3BCHEACHE
SCHEMBL10022320 0.69 KIT (0.46) KITPDGFRAFGFR3BCHEACHE
SCHEMBL31060598 0.68 KIT (1.00) KITPDGFRAFGFR3ACHECHEK1
SCHEMBL564035 0.68 KIT (1.00) KITPDGFRAFGFR3ACHECHEK1
SCHEMBL1061365 0.67 KIT (0.64) KITPDGFRAFGFR3NQO2MAP2K7
Hydrochloric Acid SCHEMBL8821075 0.67 KIT (0.97) KITPDGFRAFGFR3ACHECHEK1
Bromide SCHEMBL10413309 0.67 KIT (0.97) KITPDGFRAFGFR3ACHECHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663219-A2 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-06-07 EP claimed
WO-2005023255-A2 USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2005-03-17 WO claimed
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process RBM17, BRCA1, SMN1; SMN2 KIT 2116/4885PDGFRA 3520/4885FGFR3 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.